EY Announces Spark Biomedical CEO Daniel Powell as an Entrepreneur Of The Year® 2024 Southwest Award Finalist
19 avr. 2024 15h01 HE
|
Spark Biomedical
Dallas, TX, April 19, 2024 (GLOBE NEWSWIRE) -- Ernst & Young LLP (EY US) today announced that Daniel Powell, CEO and Founder of Spark Biomedical was named an Entrepreneur Of The Year® 2024...
Spark Biomedical Awarded $1.15M Department of Defense Phase II STTR Grant in Partnership with Battelle Memorial Institute
29 août 2023 14h52 HE
|
Spark Biomedical
DALLAS, Texas, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Aug. 29, 2023 — Spark Biomedical, Inc., a Dallas-based pioneer in wearable neurostimulation technology, was awarded a $1.15M Phase II grant to...
Spark Biomedical Launches Telehealth Services for Sparrow Ascent, Improving Patient Access to Opioid Withdrawal Treatment
08 août 2023 12h05 HE
|
Spark Biomedical
DALLAS, TX, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Spark Biomedical Launches Telehealth Services for Sparrow Ascent, Improving Patient Access to Opioid Withdrawal Treatment August 8, 2023, Dallas, TX...
Spark Biomedical’s second-generation device, Sparrow® Ascent, Receives FDA Clearance for Opioid Withdrawal Relief in Adults
11 juil. 2023 14h54 HE
|
Spark Biomedical
DALLAS, TX, July 11, 2023 (GLOBE NEWSWIRE) -- Spark Biomedical, Inc., a leading innovator in wearable neurostimulation development, is proud to announce that its next-generation, groundbreaking...
Spark Biomedical’s second-generation device, Sparrow® Ascent, Receives FDA Clearance for Opioid Withdrawal Relief in Adults
11 juil. 2023 14h38 HE
|
Spark Biomedical
DALLAS, TX, July 11, 2023 (GLOBE NEWSWIRE) -- Spark Biomedical, Inc., a leading innovator in wearable neurostimulation development, is proud to announce that its next-generation, groundbreaking...
Spark Biomedical’s second-generation device, Sparrow® Ascent, Receives FDA Clearance for Opioid Withdrawal Relief in Adults
11 juil. 2023 14h31 HE
|
Spark Biomedical
DALLAS, TX, July 11, 2023 (GLOBE NEWSWIRE) -- Spark Biomedical, Inc., a leading innovator in wearable neurostimulation development, is proud to announce that its next-generation, groundbreaking...
Five Liters sets clinical sights on novel bioelectric treatment for von Willebrand Disease
06 juil. 2023 14h37 HE
|
Spark Biomedical
DALLAS, TX and MANHASSET, NY, July 06, 2023 (GLOBE NEWSWIRE) -- Five Liters, a Dallas-based wearable neuromodulation company, is embarking on a series of groundbreaking first-in-human studies to...
Clinical trial to test wearable device as treatment for chronic pain, opioid withdrawal
17 janv. 2023 12h47 HE
|
Spark Biomedical
GALVESTON, Texas, Jan. 17, 2023 (GLOBE NEWSWIRE) -- A multi-year clinical trial at the University of Texas Medical Branch (UTMB) and Medical University of South Carolina (MUSC) will examine the use...
Feinstein Institutes for Medical Research and Spark Biomedical, Inc. advance bioelectric medicine designed to stem excessive blood loss
02 juin 2022 11h00 HE
|
Spark Biomedical
DALLAS, TX and MANHASSET, NY, June 02, 2022 (GLOBE NEWSWIRE) -- Spark Biomedical, a leader in wearable neurostimulation solutions, announced today a collaboration with The Feinstein Institutes for...
Spark Biomedical, Inc., granted $2.49M by the National Institute of Health HEAL Initiative to use neuromodulation as adjunctive therapy for neonatal opioid withdrawal syndrome
03 mars 2022 11h22 HE
|
Spark Biomedical
Dallas, Texas, March 03, 2022 (GLOBE NEWSWIRE) -- Building on Phase I clinical trial success (Jenkins, Khodaparast, et al., 2021), Spark Biomedical, Inc., and The Medical University of South...